Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03168139 | Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer(Keynote-559) | completed | Phase 1 / Phase 2 | 20 | TME Pharma AGINDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04216758 | Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer | unknown | Phase 2 | 300 | Fudan UniversityOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT04449289 | Influence of Local Anesthetic Administration on the Cancer Recurrence Rate After Pancreatic Oncologic Surgery | unknown | Phase 2 | 100 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT00313560 | ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA) | completed | Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04415385 | The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma | unknown | Phase 2 | 48 | Zhejiang Cancer HospitalOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT00255827 | Vaccine Treatment for Surgically Resected Pancreatic Cancer | completed | Phase 1 / Phase 2 | 7 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT00569387 | Vaccine Study for Surgically Resected Pancreatic Cancer | completed | Phase 2 | 73 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT00614601 | Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer | terminated | Phase 2 | 9 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02405585 | Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 10 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01896869 | FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer | completed | Phase 2 | 83 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT02261714 | Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer | completed | Phase 1 / Phase 2 | 32 | Targovax ASAINDUSTRY | 3 | May 14, 2020 | clinicaltrials |
| NCT04377048 | Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer | unknown | Phase 2 | 38 | National Taiwan University HospitalOTHER | 0 | May 6, 2020 | clinicaltrials |
| NCT02628860 | Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy(FCM) | completed | Phase 2 | 40 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 28, 2020 | clinicaltrials |
| NCT00602602 | Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | completed | Phase 2 | 19 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT04352023 | Analgesic Efficacy After Pancreatobiliary Surgery: Intravenous Versus Patient-controlled Epidural | unknown | Phase 2 | 110 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 17, 2020 | clinicaltrials |
| NCT01333124 | Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | terminated | Phase 2 | 23 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02101918 | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 23, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT03850769 | Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03885219 | Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01693523 | Minocycline Study in Pancreatic Cancer Patients | completed | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT02635971 | Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 168 | Fudan UniversityOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00727441 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 87 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00305760 | Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer | completed | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | terminated | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02358161 | Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer(MATRIX) | completed | Phase 1 / Phase 2 | 78 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT02541370 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 | completed | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01240304 | A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | University of ArkansasOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT03114631 | Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer | completed | Phase 1 / Phase 2 | 30 | The Republican Research and Practical Center for Epidemiology and MicrobiologyOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00634751 | CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma | completed | Phase 1 / Phase 2 | 48 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02749136 | Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00398086 | Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 67 | CelgeneINDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT03838029 | Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery(BC-PC) | unknown | Phase 2 | 210 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Nov 20, 2019 | clinicaltrials |
| NCT01661088 | A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients | completed | Phase 2 | 25 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT03891472 | Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer | completed | Phase 2 | 40 | Medical University of SilesiaOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02106884 | Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel(QOLINPAC) | completed | Phase 2 | 146 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT04101929 | Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen | unknown | Phase 2 | 126 | Fudan UniversityOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03610100 | Acelarin First Line Randomised Pancreatic Study(ACELARATE) | suspended | Phase 2 / Phase 3 | 328 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Oct 29, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Jul 8, 2020source: clinicaltrials